DANAHER CORP /DE/ company profile

Overview

Danaher Corporation is a Washington, D.C.-based global science and technology company focused on improving human health. Its portfolio includes more than 15 operating companies across biotechnology, life sciences, and diagnostics, providing instruments, consumables, software, and services used in biologics research and manufacturing, the study of DNA, RNA, proteins and cells, and clinical testing and treatment decision-making. Danaher describes its mission as accelerating the power of science and technology to improve human health, and its businesses are generally characterized by recurring revenue, a direct sales model, and a geographically diverse customer base.[1]

As of 2024, Danaher reported sales of $23.875 billion and approximately 63,000 employees. The company’s research, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries, with significant operations in markets including China, Denmark, Germany, Singapore, Sweden, Switzerland, and the United Kingdom.[6] [1]

Products & services

Danaher’s Diagnostics segment represented 41.0% of 2024 sales and includes Beckman Coulter, Cepheid, HemoCue, Leica Biosystems, Mammotome, and Radiometer.[9][10] Its products include clinical chemistry, immunoassay, hematology, and microbiology analyzers; laboratory automation for barcoding, centrifugation, aliquoting, storage, and sample conveyance; DNA-based molecular diagnostic systems and software; acute-care analyzers for blood gases, electrolytes, metabolites, cardiac markers, anemia, and glucose; pathology staining instruments, reagents, antibodies, microtomes, slide scanners, imaging systems, and digital pathology software; and minimally invasive breast biopsy and lesion-localization tools.[11] Named platforms include Cepheid’s GeneXpert systems, which automate sample extraction, PCR amplification, and detection in a closed-cartridge format with random-access configurations from 2 to 80 modules; Leica Biosystems’ Aperio GT 450 DX digital pathology system with LIS/LIMS connectivity and continuous rack loading; and Radiometer’s ABL90 FLEX PLUS blood gas analyzer and AQURE point-of-care IT solution.[15]

Danaher’s Life Sciences segment represented 30.7% of 2024 sales.[9] Its portfolio includes flow cytometers and cell sorters, centrifugation and sample-preparation systems, liquid-handling automation, antibodies and reagents, particle counting and characterization tools, genomic sample-prep products, confocal/compound/stereo microscopy systems and electron-microscopy specimen preparation, protein-research consumables, filtration products, and mass spectrometry platforms used to identify, analyze, and quantify elements, compounds, and biological molecules.[21] Examples include Beckman Coulter’s CytoFLEX benchtop flow cytometer platform, including configurations with up to six lasers and 21 color parameters, Biomek i-Series automated liquid handlers for routine and complex workflows, and SCIEX Triple Quad and ZenoTOF 7600 systems for targeted quantitation, MRM workflows, and high-resolution accurate-mass analysis.[26]

Danaher’s Biotechnology segment represented 28.3% of 2024 sales.[9] Its products and services center on bioprocessing and include cell-line and cell-culture media development, cell-culture media, process liquids and buffers, chromatography resins, filtration technologies, aseptic fill-finish systems, single-use hardware and consumables, manufacturing-suite design and installation, data connectivity and automation, process training, equipment services, laboratory filtration and purification tools, and membranes and reagents used in assay and diagnostic development.[31][32] Concrete offerings include Cytiva’s ÄKTA chromatography systems for protein, peptide, nucleic-acid, and vaccine purification, ÄKTA Ready single-use chromatography systems designed to reduce cleaning and cross-contamination, Xcellerex XDR single-use stirred-tank bioreactors that scale from 50 L to 2,000 L for batch, fed-batch, and perfusion processes, and Aldevron’s custom manufacturing of plasmid DNA, RNA, proteins, and gene-editing enzymes, including plasmid DNA production from 1 mg to 100 g.[33] [9]

Geographic presence

Danaher is headquartered in Washington, D.C., and has research and development, manufacturing, sales, distribution, service, and administrative facilities in more than 50 countries. As of December 31, 2024, it operated about 191 significant facilities, including 79 in the United States and 112 outside the United States, primarily in Europe. Its principal markets outside the United States are Europe and Asia.[1]

Sales are geographically diversified. In 2024, 43% of sales were in North America, 23% in Western Europe, 5% in other developed markets, and 29% in high-growth markets; 42% of total sales were in the United States, and approximately 58% of sales were generated outside the United States. On a dollar basis, 2024 revenue was $10.3 billion in North America, $5.5 billion in Western Europe, $1.3 billion in other developed markets, and $6.9 billion in high-growth markets. Danaher defines high-growth markets as Eastern Europe, the Middle East, Africa, Latin America including Mexico, and Asia excluding Japan, Australia, and New Zealand.[43]

The company’s employee base is also broadly distributed: about 24,000 associates were in North America, 20,000 in Western Europe, 3,000 in other developed markets, and 16,000 in high-growth markets as of year-end 2024. Its property, plant and equipment was concentrated in the United States ($2.585 billion net), with additional concentrations in the United Kingdom ($519 million), Sweden ($384 million), and Germany ($251 million).[7][47] [1]

Business segments

Danaher officially reports three business segments: Biotechnology, Life Sciences, and Diagnostics.[48][49] Biotechnology includes the company’s bioprocessing and discovery and medical businesses, supplying equipment, consumables, and services used in the research, development, manufacture, and delivery of biologic medicines, including monoclonal antibodies, recombinant proteins, insulin, vaccines, and cell, gene, and mRNA therapies.[50] Life Sciences provides instruments, consumables, services, and software used to study DNA, RNA, proteins, metabolites, and cells, as well as filtration products used to remove contaminants from liquids and gases.[51] Diagnostics provides clinical instruments, consumables, software, and services used in hospitals, physicians’ offices, reference laboratories, and other care settings to diagnose disease and support treatment decisions.[5]

Based on Danaher’s 2024 segment sales, Diagnostics was the largest segment at about 41% of segment revenue ($9.8 billion), followed by Life Sciences at about 31% ($7.3 billion) and Biotechnology at about 28% ($6.8 billion).[49] The company also reports an “Other” category for unallocated corporate costs and other items, but this is not presented as a reportable operating segment.[52] [48]

Company history

Danaher was established in 1984 by brothers Steven M. Rales and Mitchell P. Rales, building on an idea they had developed in the early 1980s around long-term value creation and continuous improvement. Steven Rales served as chief executive officer from 1984 to 1990, while Mitchell Rales served as president over the same period.[53]

In the late 1990s and 2000s, Danaher expanded through acquisitions that built several of its major operating platforms. It established its Test & Measurement business with the 1998 acquisition of Fluke and later added Tektronix in 2007 and Keithley Instruments in 2010. It also built a water-quality platform through acquisitions including Dr. Lange and Hach in the late 1990s, followed by Viridor Instrumentation in 2002, Trojan Technologies in 2004 and ChemTreat in 2007. In healthcare and life sciences, Danaher added Radiometer in 2004 and Leica Microsystems in 2005, then significantly broadened both diagnostics and life sciences with the acquisition of Beckman Coulter in 2011.[56]

Danaher continued reshaping its portfolio in the 2010s and 2020s. It acquired Pall in 2015 and Cepheid in 2016, while also separating Fortive in 2016. Danaher transferred its dental businesses to Envista in 2019 and completed the split-off later that year. It then expanded bioprocessing through the acquisition of GE Biopharma, later known as Cytiva, in 2020, and completed the spin-off of Veralto in 2023.[61] [53]

Sources

Continue your research

From company context to financial detail.

Explore original sources and worldwide fundamental financial data and intelligence with Finbar.

Explore DANAHER CORP /DE/ in Finbar ↗